Precision Starts Here
Pioneering and Leading Clinical-Accredited
Genome-Wide Pharmacogenomics
Trailblazing the Future of Precision Medicine
About Precision Diagnostics
Precision Diagnostics is a trailblazer and leader in clinical pharmacogenomics (PGx) and nutrigenomics (NGx), driving the real-world adoption of precision medicine and precision nutrition across Asia Pacific, located in the heart of Kuala Lumpur, Malaysia. We are proud to be awarded as the First Clinical-Recommended Genome-Wide Pharmacogenomics. We are honored by our distinguished strategic collaborations with world-leading institutions and authorities, including National Institutes of Health (Ministry of Health Malaysia), University of Oxford’s Serenox (United Kingdom), University of Liverpool (funded by the National Health Service [NHS] Race and Health Observatory, Chief Investigator NHS England’s Chair of Pharmacogenetics Professor Sir Munir Pirmohamed), National University of Singapore, Commonwealth Medical Association, and are also invited by UNESCO Chair in Bioethics. We strictly adhere to leading guidelines from reputable organisations and global standards including the United States Food and Drug Administration (FDA), the Singapore Health Sciences Authority (HSA), the Clinical Pharmacogenetics Implementation Consortium (CPIC), the Dutch Pharmacogenetics Working Group (DPWG), and the International Warfarin Pharmacogenetics Consortium (IWPC).
We go beyond testing. The PRECISE Ecosystem drives full-scale Clinical Pharmacogenomics Implementation—bridging R&D and academic education to clinical application, both locally and internationally—through strategic collaborations with leading universities, hospitals, clinics, pharmacies, professional societies, and policymakers. In parallel, the PRECISE Infrastructure delivers seamless adoption in real-world clinical practice by providing clinical-accredited and clinician-friendly reports, clinical decision support systems (CDSS), dedicated clinical support teams, and practical education. Together, these integrated solutions make pharmacogenomics adoption fast, simple and effective
As an ISO 15189 certified laboratory, Precision Diagnostics voluntarily sets higher standards and has consistently achieved good grades in multiple College of American Pathologists (CAP) External Quality Assessments (EQA), ensuring adherence to the highest global standards and best practices. We transform Research-Use-Only (RUO) tests into validated Laboratory-Developed Tests (LDTs), bringing research into clinical application. Our commitment is to elevate personalised medicine through advanced diagnostics, ensuring that our clients receive the most precise and impactful healthcare solutions available.
Our flagship clinical services—PRECISE Pharmacogenomics, PRECISE Onco+, PRECISE CardioMetabolic+, and PRECISE Nutrigenomics—empower safer, more effective, cost-efficient, and highly personalized treatment decisions across 20+ therapeutic areas, including oncology, cardiology, psychiatry, neurology, pain management and metabolic care. Our Complete Pharmacogenomics Solutions span the full spectrum—from single-drug testing to comprehensive genome-wide and whole-genome sequencing, and from rapid point-of-care diagnostics to the most cutting-edge long-read technologies—empowering both reactive and pre-emptive care.
Trusted by leading hospitals, physicians, and healthcare institutions, Precision Diagnostics is the genomic engine behind patient-first care. We don’t just deliver test results—we deliver clinical evidence, clinical actionable, and real clinical impact in personalized care. Advancing Tomorrow’s Cure!
Dr. Rebecca Tay Sook Hui
Founder & CEO
“Ingrained in evidence-based advancements and affordable diagnostics, we are determined to make personalised healthcare via precision medicine a reality for all.”
— Dr. Rebecca Tay, Founder
What Makes Us Special?
Dr Rebecca Tay’s leadership has been instrumental in shaping the success of Global Precision Diagnostics, translating scientific innovation into real-world impact. Her recent recognitions, the 2026 Study UK Alumni Award for Business & Innovation and active involvement in national precision medicine initiatives revolving nationwide authorities. It doesn’t just reflect personal achievement, but the brand’s growing credibility, influence, and leadership in advancing precision healthcare across the region.
*Click on the 2026 Study UK Alumni Award for further reading.
Pioneering Moments in Precision
Milestones & Achievements
Integration of Pharmacogenomics (PGx) and Nutrigenomics (NGx) through the signing of MOU with Island Hospital
Awarded BioNexus status by Malaysian Bioeconomy Development Corporation
Launching of PRECISE Pharmacogenomics (PGx) and Nutrigenomics (NGx)
Arranged by Bioeconomy Corporation Malaysia for Precision Diagnostics to represent Malaysia at the Healthcare Expo Taiwan.
Participated and invited as a panelist in the DBS INET 2025: Expert Industry Forum at Sunway University.
Formalised a Memoradum of Understanding (MOU) with Prof. Sir Munir to collaborate on the international DPYD study.
Collaboration with University of Oxford for the Nature Communications (2025) publication with Prof. Schuh’s team.
Invited to speak of ‘Personalised Medicine in Obesity Care: Actionable Genomic Signals for Clinical Decision-Making‘ at the Malaysian Association for the Study of Obesity (MASO).
Invited by the Biomedical Science Programme at IMU University to participate in the Industry Advisory Board (IAB).
Reappointed as CEO@PTJ, advancing research and academic collaboration with the Faculty of Medicine & Health Sciences, Universiti Putra Malaysia (UPM).
Invited as the expert speaker at the National University of Singapore (NUS) for the 120th Anniversary Celebration of NUS and the 34th Singapore Pharmacy Congress.
Our collaborative research with the National University of Singapore (NUS) and Malaysian Pharmacist Society (MPS), selected as one of 14 oral presentation at FIP World Congress in Copenhagen.
Precision Diagnostics is officially selected for Malaysia’s Bio-Based Accelerator Programme.
Received award for the ‘Largest Clinically Accredited Genome-Wide Pharmacogenomics Campaign‘ at the 30th Anniversary Malaysia Book of Records.
Invited as a speaker at the International Congress of Pathology and Laboratory Medicine (ICPaLM) 2025.
Invited as a panelist at CPHI South East Asia: Pharmacogenomics – Drugs That Kill?.
Launching of PRECISE Pharmacogenomics (PGx) and Nutrigenomics (NGx) at RSU Royal Prima Medan.
Participated in the Malaysia Medical Association Integrative Medicine Conference on Embracing Inclusivity with Diversity.
Participated in the Malaysia-Indonesia Biopartnering Initiative introducing PRECISE Pharmacogenomics with the Ministry of Health, Indonesia.
Launching of PRECISE Pharmacogenomics at Oriental Melaka Straits Medical Centre, Melaka.
Discusion
with Institute of Medical Research (Ministry of Health) on the implementation of Pharmacogenomics in the Malaysia healthcare system.
Participated in the Sunway Mega Roadshow as the Largest Clinical Accredited Genome-Wide Pharmacogenomics Campaign recognised by the Malaysia Book of Records.
Signed a Memorandum of Understanding (MoU) with ReGen Rehab Hospital (ReGen) and Sunway Multicare Pharmacy (SMP).
Launching and expansion of PRECISE Pharmacogenomics at Bagan Specialist Centre, Penang.
Participated in the Oncology Workshop 2024 hosted by Regency Specialist Hospital for Personalised Prescribing in Oncology – The Role of Pharmacogenomics for Safer and More Effective Treatment and The Role of Medical Nutrition Therapy in Cancer.
Invited as a panelist by the International Medical University (IMU) on the Digital Frontiers: Unleashing AI and Innovation in Malaysia’s Healthcare Sector.
Signed a Memorandum of Understanding (MoU) with Monash University Malaysia.
Sponsored Precision Medicine and Scientific Wellness (PMedS) Association for the 1ˢᵗ Malaysia Pharmacogenomics Summit 2024.
Participated in the Association of Private Hospitals Malaysia (APHM) International Healthcare Conference and Exhibition 2024.
Signed a Memorandum of Understanding (MOU) with the Commonwealth Medical Association.
Dr Rebecca inaugurated as the Chief Executive Officer@FPSK titled Leadership in Healthcare.
Invited as an industry partner panelist by International Medical University (IMU) to a forum on Career Opportunities for Biomedical Scientists in the Post Pandemic Era.
Participated in the Malaysian Association for the Study of Obesity (MASO) on Curbing Obesity: A Shared Responsibility.
Attended and presented a talk, Precision Medicine: Revolutionizing Pathology in Genomic Era in the International Congress of Pathology & Laboratory Medicine (ICPALM).
Signed a research collaboration agreement with the National University of Singapore.
Awarded by the Malaysia Book of Records for the First Clinical Recommended Genome-Wide Pharmacogenomics test.
Global Precision Diagnostics Sdn Bhd (hereafter Precision Diagnostics) was founded by Dr Rebecca Tay.
Our Vision
Revolutionise global healthcare by delivering the best solutions in diagnostics, enabling every individual on the planet access to personalised, precise and affordable healthcare solutions.
Our Mission
Empower patients, healthcare professionals and the community with reliable personalised healthcare by utilising cutting-edge technology to accelerate the global adoption of precision medicine and scientific wellness and to make affordable, innovative diagnostics universally accessible, supporting our vision to revolutionise global healthcare.
Comprehensive Clinical Implementation Solutions
Offering total pharmacogenomic solutions covering >1000 genes and >500 medications, supported by Clinical Decision Support Systems (CDSS), Doctor’s Portal, electronic health records (EHR), electronic medical records (EMR), pharmacogenomics-certified support team, clinical implementation training, and strict compliance with ethical, data protection and regulatory standards.
Pioneering & Leadership
Pioneering and leading genome-wide pharmacogenomics in clinical implementation and applications, in strategic collaboration with global renowned institutions.
Clinical-Accredited
PRECISE Pharmacogenomics reports are clinically accredited and tailored to assist clinicians in conducting personalized treatment based on genetic profiles.
Patient /
Customer-Centric
Compassionate and committed to delivering innovative, affordable, and personalised services.
Quality Excellence &
Regulatory Compliance
Strictly adheres to international best practices and recognized regulatory bodies, including the U.S. Food and Drug Administration (FDA), Clinical Pharmacogenetics Implementation Consortium (CPIC), Association for Molecular Pathology (AMP), Dutch Pharmacogenetics Working Group (DPWG), International Warfarin Pharmacogenetics Consortium (IWPC), National Institute for Health and Care Excellence (NICE), and National Comprehensive Cancer Network (NCCN); is accredited with ISO 15189 certification and has consistently achieved good grades in multiple College of American Pathologists (CAP) External Quality Assessments (EQA).
Complete Pharmacogenomics Solution
Total solutions from single-drug testing to comprehensive genome-wide and whole-genome sequencing, and from rapid point-of-care diagnostics to the most cutting-edge long-read technologies—empowering both reactive and pre-emptive care.
Distinguished Expertise
Led by a multidisciplinary team of pathologists, clinicians, pharmacists, genetic counsellors, bioinformaticians, top scientists and researchers, as well as policymakers.
Breakthrough Advancements & Esteemed Collaborations
Partnerships with world-renowned institutions for research breakthroughs, clinical trials, services provision, expert advisories, joint conferences, clinician education, student internships, and more.
shaping The future of healthcare
Join Us on the Journey
At Precision Diagnostics, we go beyond diagnostics. We’re bringing the future of healthcare to you happening here and now, where treatments are safer, more effective, and uniquely tailored to each person’s DNA.
COLLABORATE WITH PRECISION DIAGNOSTICS
Partner With Us Today
We welcome the opportunity to work together in bringing precision medicine closer to the community.
